跳至主要内容
临床试验/NCT01439061
NCT01439061已完成不适用

Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using "Easypod™" Electromechanical Device for Growth Hormone Treatment in Italy

Merck KGaA, Darmstadt, Germany1 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2012年3月31日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
220
试验地点
1
主要终点
Mean percent of daily recorded adherence

研究概览

简要总结

This is an Italian, Multicentre, Observational Study to study Adherence and Long Term Outcomes of Therapy in paediatric subjects using easypod™ electromechanical device for growth hormone treatment to assess the level of adherence of subject receiving SAIZEN® via easypod™.

详细描述

Subjects will be enrolled in a multicenter longitudinal observational study. Parents or guardian and subjects (when applicable) will provide their Informed Consent to upload their data for population-based analyses and, ultimately, clinical outcomes. Adherence data will be primarily derived from the easypod™ device combined with physician data entry of outcome measures. Data will be collected retrospectively and prospectively. This will allow the establishment of adherence profiles and subsequent clinical outcomes. Collected data will be also analyzed in a multinational pooled analysis of comparable national studies.

Primary Objective:

• To assess the level of adherence of subjects receiving SAIZEN® via easypod™

Secondary Objectives:

  • To describe the impact of adherence on clinical outcomes for subject receiving SAIZEN® via easypod™
  • To identify adherence subject profiling
  • To asses the impact of adherence on Insulin-like Growth Factor 1 (IGF1) (i.e. above, below or within normal ranges)

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
2 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Over the age of >2 years
  • Under <18 years of age, or over 18 without fusion of growth plates
  • Parents' or guardian's written informed consent, given before entering data into the observational study, with the understanding that the subject or parents/guardian may withdraw consent at any time without prejudice to future medical care. If the child is old (over 18 without fusion of growth plates) or able to give written informed consent, a separate assent form will be given

排除标准

  • Subjects taking growth hormone in whom growth plates have fused (i.e. for taking growth hormone for it's metabolic effects)
  • Contra-indications to SAIZEN® as defined in the Summary of Product Characteristics (SmPC)
  • Use of an investigational drug or participation in another interventional clinical study

结局指标

主要结局

Mean percent of daily recorded adherence

时间窗: At least 6 months and up to 5 years

次要结局

  • Correlation of adherence and growth outcome after each year of SAIZEN® treatment with easypod™(At least 6 months and up to 5 years)
  • Subject adherence profile based on age, gender, indication, self-injection or not, time on treatment(At least 6 months and up to 5 years)
  • Correlation of adherence with current IGF-1 status (i.e. above, below or within normal ranges)(At least 6 months and up to 5 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验